Key Takeaways
- Revenue grew 8.9% YoY despite macro headwinds: Trade policy uncertainty, tariff revisions, Middle East tensions, Red Sea disruption, container shortages, port congestion, and volatile crude oil prices all impacted execution, yet revenue growth was driven by newer products and volume expansion in existing markets.
- Product mix is shifting deliberately toward oral solids: The injectable share fell from 70% to 50% as the company uses simpler-to-enter oral solids to grow the top line, then pitches injectables to those customers, keeping the injectable business niche for better margins.
- Pune plant is the near-term catalyst: Validation and stability batches are complete, the final audit is done, and a commercial license is expected this month (August 2025), with commercial production starting by end of August or first week of September.
- EBITDA margin improvement is a FY27 story, not FY26: New products lack economies of scale for 3-4 years; the first batch of products turns mature in FY27, so EBITDA margins are expected to improve in that year. FY26 EBITDA margin guidance is around 15%.
- What to watch next quarter: Whether the Pune plant commercial license arrives on schedule and production begins, whether supply chain bottlenecks normalize as expected, and whether nutraceutical revenues begin their promised recovery.
Pune Plant & Capacity Expansion
- Pune plant nearing commercial start: Validation batches, stability batches, and the final audit are all complete; the company expects a commercial license this month (August 2025), with commercial production beginning by end of August or first week of September.
- Regulatory delay explained: New Schedule M revised GMP guidelines from the Government of India created an online system bottleneck; the company was processed ahead of many others who have been waiting 8-9 months.
- SPL Infusion plant ramp-up: Expected to start within August 2025, ramp to 65-70% capacity in the first year, and reach around INR75-80 crores of top line.
- Prague JV operational: Small order processing has already started and commercialization is on; results will be reported once the year ends in December for European markets, with income shown in the balance sheet in Q4.
Ashwani Khemka: "Now there's an online system. In the online system, there are a lot of companies that are in the pipeline. We are, in fact, ahead. There are many companies in India who have been in line for the last 8 to 9 months. And once those are processed, they can't do. For us, it has been done out of the way to take it ahead on the CDSCO website, Delhi."
Revenue & Product Mix
- Injectable revenue declined sequentially on order lumpiness: No particular business reason; Q1 is a leaner quarter and Q3/Q4 are always better; the company's small revenue size makes quarterly swings from order timing more visible.
- Oral solids are the deliberate growth engine: The company is using oral solids, which are simpler to enter markets with, to grow the top line, then pitching injectables to those same customers; the injectable business is kept niche to earn better margins.
- Nutraceutical revenue declined on geopolitical priorities: In war zones where the company is active, first preference goes to medicines over nutraceuticals; management expects nutraceutical revenues to recover and grow from here.
- New product additions continue: Around eight products were added to the portfolio in Q1 and Q2 combined, following around 30 in FY24 and around 20 in FY25.
- The company does not track revenue from recently launched products: When asked whether it tracks how much revenue comes from products launched in the last two years, management said no, not at the moment.
Srivardhan Khemka: "Sir, no particular reason. As you know, the total size of the company's revenue is not that large. It is just order lumpiness. This quarter, it has dropped. The next quarter, it will pick up. It's nothing to do specifically with the business, per se."
Margins & Cost Structure
- Gross margin declined slightly under market pressure: The overall market has been under pressure due to sales; the company managed to grow revenue despite these pressures but faced a small decline in gross margins, which was offset by controlling other expenses, resulting in a stable level overall.
- Other expenses dropped sequentially on cost optimization: The decline from INR4 cr to INR2.5 cr was due to cost optimization and fewer plant inspections and audits in the current quarter compared to the previous quarter.
- Depreciation rose 13% YoY on recent capex: Capex done recently has kicked in depreciation in the current quarter; this will be a steady number going forward unless another major capex is undertaken.
- Debt reduced modestly: Debt fell from around INR8 crores last quarter to INR6 crores currently due to minor repayments on working capital limits, which will not be steady going forward.
Srivardhan Khemka: "What happens is when we add new products, the economies of scale are not there. Once the product is mature, like 3-4 years, then the economies of scale kick in and then our EBITDA margins are bound to improve. So what we see is the first batch of products will turn mature in, say, FY '27. So, we see the EBITDA margins to improve in that year."
Geographic & Segment Outlook
- LATAM is the near-term growth driver: For this year and next year, LATAM is going to be the growth driver for the company.
- LATAM logistics remain a bottleneck: Shipping products to Latin America faced lack of container availability due to vessel shortages heading in that direction, with Chinese carriers also creating some kind of choke.
- Franco-African markets progressing slowly: The 48 products filed in Franco-African nations are still waiting for registrations with no concrete development; however, the company is starting to see demand for certain products in the tender business and is filing for expedited registrations where its price is better and dossier is perfect.
- Franco-African strategy is slow but margin-rich: The market is very slow because it is a very branded business; the company is planning to hire agents and teams out there, and while scale-up will be slow, margins will be better.
- CDMO order book supports 20% growth: The company already has an order book to deliver a minimum 20% growth in CDMO this year over what was done last year.
Srivardhan Khemka: "We are planning to even hire agents and teams out there. So, the scale-up on that front will be slow, but the margins will be better."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Pune plant commercial production | Commercial license expected, production to start | End of August or first week of September 2025 |
| SPL Infusion plant ramp-up | Reach 65-70% capacity, INR75-80 cr top line | First year of operation |
| Full-year FY26 revenue | Around INR75-80 crores | FY26 |
| Full-year FY26 EBITDA margin | Around 15% at EBITDA level for base business | FY26 |
| EBITDA margin improvement | Economies of scale kick in as first batch of products mature | FY27 |
| CDMO growth | Minimum 20% growth over prior year, order book already in hand | FY26 |
| Nutraceutical revenue | Recovery and growth from current levels | From here on |
| Supply chain bottlenecks | Temporary bottlenecks expected to normalize progressively | Over the year |
| Prague JV income recognition | Income shown in balance sheet | Q4 FY26 |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Revenue | ₹17.9 cr, +8.9% YoY |
| EBITDA | ₹2.7 cr, +10.8% YoY |
| EBITDA margin | 15.0%, vs 14.7% in Q1 FY25 |
| Profit after tax | ₹1.7 cr, flat YoY due to higher depreciation and interest expense |
| Revenue guidance FY26 | ₹75-80 cr, confirmed by management |
| EBITDA margin guidance FY26 | ~15% for base business |
| Export-domestic mix | 73.7% export, 26.3% domestic |
| Product mix: injectables, tablets, nutraceuticals | 50.2%, 49.3%, 0.4% respectively |
| Injectable revenue (sequential) | ₹9 cr, down from ₹13 cr in Q4 FY25 (per an analyst's math) |
| New products added | 8 in Q1 and Q2 combined |
| CDMO business growth target FY26 | ~20% minimum |
| SPL Infusion plant capacity ramp-up | 65-70% expected in first year |
| SPL Infusion plant revenue potential | ₹75-80 cr top line |
| Debt | ₹6 cr, down from ~₹8 cr in Q4 FY25 |
| Trade receivables | ~₹8 cr |